Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone by systemic versus systemic plus intratympanic routes for salvage treatment of sudden sensorineural hearing loss
ChiCTR2000028818Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methylprednisolone in idiopathic sudden sensorineural hearing loss (ISSNHL) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Pure tone average. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
methylprednisolone
03
Conditions
idiopathic sudden sensorineural hearing loss (ISSNHL)
Beyond the preview
Go deeper on ChiCTR2000028818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028818.